Table E1.
Data summarizing responses to generic questions
| Number | Question | Subcategories | Adult immunology, n (%) | Pediatric immunology, n (%) | Adult allergy, n (%) | Pediatric allergy, n (%) | Total, n (%) |
|---|---|---|---|---|---|---|---|
| Personal protective equipment (PPE) and screening | |||||||
| 1 | Screening | No. of respondents | 30 (100) | 7 (100) | 30 (93.8) | 27 (90) | 94 (94.9) |
| 1a | When patients arrive for appointments or procedures, were/are you screening for COVID-19 infection—week commencing February 3, 2020? | No screening | 14 (46.7) | 2 (28.6) | 14 (46.7) | 13 (48.1) | 43 (45.7) |
| Screening questionnaire (eg, cough and fevers) | 9 30) | 2 (28.6) | 8 (26.7) | 4 (14.8) | 23 (24.5) | ||
| Temperature measurements | 4 (13.3) | 1 (14.3) | 3 (10) | 0 (0) | 8 (8.5) | ||
| COVID-19 swab | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| 1b | When patients arrive for appointments or procedures, were/are you screening for COVID-19 infection—week commencing April 6, 2020? | No screening | 10 (33.3) | 0 (0) | 11 (36.7) | 10 (37) | 31 (33) |
| Screening questionnaire (eg, cough and fevers) | 24 (80) | 5 (71.4) | 25 (83.3) | 17 (63) | 71 (75.5) | ||
| Temperature measurements | 18 (60) | 2 (28.6) | 21 (70) | 6 (22.2) | 47 (50) | ||
| COVID-19 swab | 1 (3.3) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) | ||
| 1c | When patients arrive for appointments or procedures, were/are you screening for COVID-19 infection—week commencing May 8, 2020 | No screening | 6 (20) | 0 (0) | 10 (33.3) | 10 (37) | 26 (27.7) |
| Screening questionnaire (eg, cough and fevers) | 25 (83.3) | 4 (57.1) | 26 (86.7) | 19 (70.4) | 74 (78.7) | ||
| Temperature measurements | 19 (63.3) | 3 (42.9) | 21 (70) | 7 (25.9) | 50 (53.2) | ||
| COVID-19 swab | 1 (3.3) | 2 (28.6) | 0 (0) | 0 (0) | 3 (3.2) | ||
| 2 | PPE | No. of respondents | 30 (100) | 7 (100) | 31 (96.9) | 21 (70) | 89 (89.9) |
| 2a | For procedures with asymptomatic patients (eg, skin testing, VIT, omalizumab, challenges, and immunoglobulin) were you using the following PPE week commencing February 3, 2020? | Surgical mask (fluid- resistant) | 0 (0) | 1 (14.3) | 0 (0) | 3 (14.3) | 4 (4.5) |
| Filtering facepiece 3 mask | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Single-use plastic apron | 3 (10) | 2 (28.6) | 4 (12.9) | 6 (28.6) | 15 (16.9) | ||
| Long-sleeved gown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Eye protection | 0 (0) | 0 (0) | 0 (0) | 1 (4.8) | 1 (1.1) | ||
| 2b | For procedures with asymptomatic patients (eg, skin testing, VIT, omalizumab, challenges, and immunoglobulin) were you using the following PPE week commencing April 6, 2020? | Surgical mask (fluid- resistant) | 28 (93.3) | 5 (71.4) | 27 (87.1) | 17 (81) | 77 (86.5) |
| Filtering facepiece 3 mask | 2 (6.7) | 0 (0) | 1 (3.2) | 0 (0) | 3 (3.4) | ||
| Single-use plastic apron | 27 (90) | 5 (71.4) | 26 (83.9) | 17 (81) | 75 (84.3) | ||
| Long-sleeved gown | 1 (3.3) | 0 (0) | 1 (3.2) | 1 (4.8) | 3 (3.4) | ||
| Eye protection | 13 (43.3) | 0 (0) | 13 (41.9) | 2 (9.5) | 28 (31.5) | ||
| 2c | For procedures with asymptomatic patients (eg, skin testing, VIT, omalizumab, challenges, and immunoglobulin), were you using the following PPE week commencing May 8, 2020? | Surgical mask (fluid- resistant) | 30 (100) | 7 (100) | 31 (100) | 20 (95.2) | 88 (98.9) |
| Filtering facepiece 3 mask | 3 (10) | 0 (0) | 2 (6.5) | 0 (0) | 5 (5.6) | ||
| Single-use plastic apron | 28 (93.3) | 6 (85.7) | 30 (96.8) | 18 (85.7) | 82 (92.1) | ||
| Long-sleeved gown | 1 (3.3) | 0 (0) | 1 (3.2) | 1 (4.8) | 3 (3.4) | ||
| Eye protection | 14 (46.7) | 2 (28.6) | 16 (51.6) | 4 (19) | 36 (40.4) | ||
| Service provision | |||||||
| 3 | Has there been a change to out-of-hours (outside of 9 am to 5 pm, weekends, and public holidays) provision? | No. of respondents | 30 (100) | 7 (100) | 32 (100) | 30 (100) | 99 (100) |
| Not applicable; no out-of- hours provision pre–COVID-19 | 18 (60) | 4 (57.1) | 26 (81.3) | 22 (73.3) | 70 (70.7) | ||
| No change (out-of-hours service continues) | 12 (40) | 3 (42.9) | 6 (18.8) | 8 (26.7) | 29 (29.3) | ||
| Out-of-hours service withdrawn as a result of COVID-19 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Research | |||||||
| 4 | Have there been changes in your research activity? | No. of respondents | 30 (100) | 7 (100) | 32 (100) | 30 (100) | 99 (100) |
| Not applicable; not involved in research pre–COVID-19 | 5 (16.7) | 0 (0) | 7 (21.9) | 18 (60) | 30 (30.3) | ||
| No change | 8 (26.7) | 2 (28.6) | 6 (18.8) | 3 (10) | 19 (19.2) | ||
| Yes, moved to remote research | 2 (6.7) | 3 (42.9) | 1 (3.1) | 3 (10) | 9 (9.1) | ||
| Yes, all research suspended | 14 (46.7) | 2 (28.6) | 17 (53.1) | 5 (16.7) | 38 (38.4) | ||
| Reduced numbers or other | 1 (3.3) | 0 (0) | 1 (3.1) | 1 (3.3) | 3 (3) | ||
| Referrals | |||||||
| 5 | Referrals | No. of respondents | 30 (100) | 7 (100) | 31 (96.9) | 29 (96.7) | 97 (98) |
| 5a | Did you triage referrals pre–COVID-19? | Yes, all | 27 (90) | 6 (85.7) | 27 (87.1) | 22 (75.9) | 82 (84.5) |
| Some | 3 (10) | 1 (14.3) | 3 (9.7) | 7 (24.1) | 14 (14.4) | ||
| No, none | 0 (0) | 0 (0) | 1 (3.2) | 0 (0) | 1 (1) | ||
| 5b | Do you triage referrals since COVID-19? | Yes, all | 27 (90) | 6 (85.7) | 29 (93.5) | 25 (86.2) | 87 (89.7) |
| Some | 2 (6.7) | 1 (14.3) | 1 (3.2) | 4 (13.8) | 8 (8.2) | ||
| No, none | 1 (3.3) | 0 (0) | 1 (3.2) | 0 (0) | 2 (2.1) | ||